Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep:239:117047.
doi: 10.1016/j.bcp.2025.117047. Epub 2025 Jun 7.

SLC1A5 mediates myocardial damage after myocardial infarction by triggering cardiomyocyte ferroptosis

Affiliations

SLC1A5 mediates myocardial damage after myocardial infarction by triggering cardiomyocyte ferroptosis

Dong Wang et al. Biochem Pharmacol. 2025 Sep.

Abstract

Myocardial infarction (MI) has become a major disease that causes significant global mortality. Notably ferroptosis may exert a key effect on myocardial injury after MI. As the glutamine transporter on the cell membrane, solute carrier family 1 member 5 (SLC1A5) plays a role as a ferroptosis-inducing gene and has a mediating effect on cell ferroptosis. However, whether SLC1A5 is involved in mediating cardiomyocyte ferroptosis and myocardial injury after MI remains to be further elucidated. In the present study, we investigated whether SLC1A5 mediated myocardial injury after MI by triggering cardiomyocyte ferroptosis in vivo and in vitro. Based on our findings, SLC1A5 exhibited crucial mediating effects on post-MI cardiomyocyte ferroptosis and myocardial injury, and these effects were stimulated by SLC1A5 overexpression, but inhibited by ferrostatin-1 (a ferroptosis inhibitor)and V9302 (a SLC1A5 inhibitor). In conclusion, our results revealed a novel molecular mechanism of ferroptosis regulated by SLC1A5, which is essential for cardiomyocyte ferroptosis pathogenesis and myocardial injury post-MI.

Keywords: Ferroptosis; Myocardial infarction; SLC1A5.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MeSH terms

Substances